Clinical trial · no report yet · Phase 3
NCT06396065
Phase III Study of AK112 for NSCLC Patients
- NCT06396065 ↗
- Active, not recruiting
- Summit Therapeutics
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 99 | |
| YouTube | 11 | |
| Podcasts | 11 | |
| X videos | 4 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Non-Squamous Non-small Cell Lung Cancer
- Interventions
- AK112 Injection; Placebo Injection
- Arms
- AK112 in combination with Pemetrexed and Carboplatin · Experimental
- Placebo in combination with Pemetrexed and Carboplatin · Active comparator
- Enrollment
- 420
- Primary outcomes
- Progression-free survival (PFS)
- Overall Survival (OS) in the ITT population
- Sponsor
- Summit Therapeutics with Akeso
- Start
- May 4, 2023
- Primary completion
- Apr 12, 2025
- Results posted
- No
- Registry record
- NCT06396065 · updated Jul 28, 2026
Publications
linked from the registry- Le X, Passaro A, Zhao Y, Huang Y, Laskin J, Rodriguez-Abreu D, Calles A, Bazhenova L, Lo Russo G, Leighl NB, Cappuzzo F, Girard N, Popat S, Fang W, Luo Y, Li W, He Z, Zhao H, Li M, Song Q, Zhao H, El Darsa H, Monnet I, Cobo Dols M, Garcia Campelo R, Jotte R, Berz D, Spira A, Perol M, Nagasaka M, West H, Styles L, Li J, Clow F, Goldman J, Zhang L. Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2026 Sep;27(9):1094-1109. doi: 10.1016/S1470-2045(26)00282-2. PubMed 42636833